LLY – Eli Lilly and Company
Eli Lilly and CompanyLLY
$1,047.96Name : Eli Lilly and Company
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $939,446,304,768.00
EPSttm : 22.95
Eli Lilly and Company
$1,047.96
1.10%$11.41Float Short %
0.82
Margin Of Safety %
-6
Put/Call OI Ratio
1.07
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
7.48
Price
1038.12
Target Price
1236.73
Analyst Recom
1.53
Performance Q
5.02
Relative Volume
1.06
Beta
0.4
Ticker: LLY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-14 | LLY | 1073.8 | 0.96 | 0.88 | 386324 |
| 2026-01-15 | LLY | 1032.07 | 0.96 | 0.96 | 390377 |
| 2026-01-16 | LLY | 1039.43 | 0.95 | 0.76 | 404145 |
| 2026-01-20 | LLY | 1041.29 | 1.01 | 1.00 | 284995 |
| 2026-01-21 | LLY | 1079.49 | 1.02 | 0.86 | 293067 |
| 2026-01-22 | LLY | 1087.33 | 1.03 | 0.84 | 302777 |
| 2026-01-23 | LLY | 1065.28 | 1.03 | 1.04 | 313585 |
| 2026-01-26 | LLY | 1062.86 | 1.03 | 1.44 | 291318 |
| 2026-01-27 | LLY | 1038 | 1.04 | 1.01 | 299092 |
| 2026-01-28 | LLY | 1023.51 | 1.05 | 0.95 | 308535 |
| 2026-01-29 | LLY | 1023.74 | 1.04 | 0.81 | 319692 |
| 2026-01-30 | LLY | 1037.91 | 1.04 | 0.71 | 322679 |
| 2026-02-02 | LLY | 1043.58 | 1.06 | 1.01 | 296369 |
| 2026-02-04 | LLY | 1106.23 | 1.07 | 1.04 | 319938 |
| 2026-02-05 | LLY | 1018.67 | 1.06 | 0.82 | 328113 |
| 2026-02-06 | LLY | 1058.18 | 1.07 | 0.75 | 336799 |
| 2026-02-09 | LLY | 1044.76 | 1.06 | 0.67 | 310644 |
| 2026-02-10 | LLY | 1025 | 1.06 | 0.78 | 322349 |
| 2026-02-11 | LLY | 1014.84 | 1.06 | 0.72 | 330459 |
| 2026-02-12 | LLY | 1038.95 | 1.07 | 0.24 | 334616 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-14 | LLY | 1073.32 | 35.8 | 12298.9 | 23.66 |
| 2026-01-15 | LLY | 1030.39 | 35.8 | 11038.5 | 23.66 |
| 2026-01-16 | LLY | 1038.40 | 35.8 | 12605.3 | 23.66 |
| 2026-01-20 | LLY | 1041.00 | 35.4 | 12510.0 | 23.66 |
| 2026-01-21 | LLY | 1078.52 | 35.4 | 13660.9 | 23.66 |
| 2026-01-22 | LLY | 1087.38 | 35.4 | 12708.1 | 23.66 |
| 2026-01-23 | LLY | 1064.29 | 35.4 | 11687.3 | 23.66 |
| 2026-01-26 | LLY | 1062.75 | 32.7 | 12373.2 | 23.66 |
| 2026-01-27 | LLY | 1039.09 | 31.3 | 11920.5 | 23.66 |
| 2026-01-28 | LLY | 1023.80 | 31.3 | 12170.2 | 23.66 |
| 2026-01-29 | LLY | 1024.14 | 31.3 | 12709.0 | 23.66 |
| 2026-01-30 | LLY | 1037.15 | 30.6 | 13140.2 | 23.66 |
| 2026-02-02 | LLY | 1044.13 | 30.6 | 12932.1 | 23.66 |
| 2026-02-03 | LLY | 1004.00 | 30.6 | 11356.7 | 23.66 |
| 2026-02-04 | LLY | 1107.50 | 30.6 | 16309.0 | 23.66 |
| 2026-02-05 | LLY | 1020.88 | 128.9 | 9975.0 | 33.30 |
| 2026-02-06 | LLY | 1057.89 | 128.9 | 13965.6 | 33.30 |
| 2026-02-09 | LLY | 1044.67 | 125.8 | 13121.0 | 34.15 |
| 2026-02-10 | LLY | 1025.69 | 117.4 | 12928.2 | 34.12 |
| 2026-02-12 | LLY | 1038.12 | 117.6 | 14382.9 | 34.28 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-14 | LLY | -4.19 | -1.11 | 0.82 |
| 2026-01-15 | LLY | -4.20 | -1.11 | 0.82 |
| 2026-01-16 | LLY | -4.20 | -1.11 | 0.82 |
| 2026-01-20 | LLY | -4.20 | -1.13 | 0.82 |
| 2026-01-21 | LLY | -4.20 | -1.13 | 0.82 |
| 2026-01-22 | LLY | -4.20 | -1.13 | 0.82 |
| 2026-01-23 | LLY | -4.20 | -1.13 | 0.82 |
| 2026-01-26 | LLY | -3.93 | -1.15 | 0.82 |
| 2026-01-27 | LLY | -3.93 | -1.15 | 0.82 |
| 2026-01-28 | LLY | -3.93 | -1.15 | 0.90 |
| 2026-01-29 | LLY | -3.93 | -1.15 | 0.90 |
| 2026-01-30 | LLY | -3.93 | -1.15 | 0.90 |
| 2026-02-02 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-03 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-04 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-05 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-06 | LLY | -3.93 | -1.17 | 0.90 |
| 2026-02-09 | LLY | -3.93 | -0.71 | 0.90 |
| 2026-02-10 | LLY | -3.93 | -0.71 | 0.90 |
| 2026-02-11 | LLY | -3.93 | -0.71 | 0.82 |
| 2026-02-12 | LLY | -3.93 | -0.71 | 0.82 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
7.27
Avg. EPS Est. Next Quarter
8.05
Insider Transactions
-3.93
Institutional Transactions
-0.71
Beta
0.4
Average Sales Estimate Current Quarter
17335
Average Sales Estimate Next Quarter
19411
Fair Value
977.9
Quality Score
97
Growth Score
100
Sentiment Score
62
Actual DrawDown %
8.5
Max Drawdown 5-Year %
-34.5
Target Price
1236.73
P/E
45.23
Forward P/E
25.12
PEG
0.95
P/S
15.06
P/B
41.27
P/Free Cash Flow
105.86
EPS
22.96
Average EPS Est. Cur. Y
34.28
EPS Next Y. (Est.)
41.76
Target Price Estimates Raised
1
Target Price Estimates Lowered
Profit Margin
31.66
Relative Volume
1.06
Return on Equity vs Sector %
49.5
Return on Equity vs Industry %
41.3
EPS 1 7Days Diff
0.9
EPS 1 30Days Diff
1.3
EBIT Estimation
14382.9
Eli Lilly and CompanySector: Healthcare
Industry: Drug Manufacturers - General
Employees:
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
stock quote shares LLY – Eli Lilly and Company Stock Price stock today
news today LLY – Eli Lilly and Company stock forecast ,stock prediction 2023 2024 2025
marketwatch LLY – Eli Lilly and Company yahoo finance google finance
stock history LLY – Eli Lilly and Company invest stock market
stock prices LLY premarket after hours
ticker LLY fair value insiders trading